FEBS Letters:癌症抑制相关因子RBM5有效促进DHX15解旋酶活性

2012-04-10 北京生命科学研究所 北京生命科学研究所

2012年3月17日,北京生命科学研究所李夏璐研究小组在《FEBS Letters》杂志在线发表文章,报道了癌症抑制因子RBM5与剪接因子DHX15直接相互作用,从而提高了DHX15核酸解旋酶的活性。 在肺癌等多种癌症发生早期,都伴随有染色体3p21.3区域的缺失,RBM5基因则位于这段区域内。前期研究发现,RBM5的高表达能促进细胞凋亡,低表达则诱导细胞癌化。因此,RBM5一直以来被认为是癌症

2012年3月17日,北京生命科学研究所李夏璐研究小组在《FEBS Letters》杂志在线发表文章,报道了癌症抑制因子RBM5与剪接因子DHX15直接相互作用,从而提高了DHX15核酸解旋酶的活性。

在肺癌等多种癌症发生早期,都伴随有染色体3p21.3区域的缺失,RBM5基因则位于这段区域内。前期研究发现,RBM5的高表达能促进细胞凋亡,低表达则诱导细胞癌化。因此,RBM5一直以来被认为是癌症抑制相关因子。最近的两项研究表明,该蛋白在调节凋亡相关因子的选择性剪接中发挥作用。然而,对于RBM5在剪接调控中的作用机理仍了解甚少。

本文首先通过免疫共沉淀的方法,发现了两个重要的剪接体组份:PRP19和DHX15是RBM5的两个新的核内结合蛋白。进一步体外实验证实,RBM5与这两个剪接因子之间存在着直接的相互作用并能有效促进DHX15的解旋酶活性。解旋酶直接参与动态调控剪接复合体成熟过程中发生的一系列RNA:蛋白和RNA:RNA相互作用。这项工作提示了RBM5参与剪接调控的可能作用机理,为RBM5的生物学功能研究提供了新的线索和依据。(生物谷 bioon.com)

doi:10.1016/j.febslet.2012.02.052
PMC:
PMID:

Tumor suppressor RBM5 directly interacts with the DExD/H-box protein DHX15 and stimulates its helicase activity

Zhaoyang Niua, Wenxing Jinb, Libo Zhang, Xialu Li

RNA binding motif protein 5 (RBM5) is a candidate tumor suppressor gene. Recent studies showed that RBM5 functions as an alternative splicing regulator of apoptosis-related genes. Here, we identify DHX15 and PRP19, two spliceosome components, as novel RBM5-interacting partners. We then show that the G-patch domain of RBM5 is indispensable for its ability to interact with DHX15. Strikingly, we find that RBM5 stimulates the helicase activity of DHX15 in a G patch domain-dependent manner in vitro. Helicase activities play critical roles in modulating pre-mRNA splicing. Our findings thus suggest a new mechanism underlying the regulatory roles of RBM5 in pre-mRNA splicing.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=14709, encodeId=ce3014e0909, content=it's good !, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Mon Jan 26 15:16:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793152, encodeId=765d1e931524b, content=<a href='/topic/show?id=3bec151e616' target=_blank style='color:#2F92EE;'>#RBM5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15176, encryptionId=3bec151e616, topicName=RBM5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Aug 11 17:45:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038373, encodeId=a89d20383e38b, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Aug 13 14:45:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878049, encodeId=b2ca18e8049c3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Aug 28 21:45:00 CST 2012, time=2012-08-28, status=1, ipAttribution=)]
    2015-01-26 loveios

    it's good !

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=14709, encodeId=ce3014e0909, content=it's good !, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Mon Jan 26 15:16:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793152, encodeId=765d1e931524b, content=<a href='/topic/show?id=3bec151e616' target=_blank style='color:#2F92EE;'>#RBM5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15176, encryptionId=3bec151e616, topicName=RBM5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Aug 11 17:45:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038373, encodeId=a89d20383e38b, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Aug 13 14:45:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878049, encodeId=b2ca18e8049c3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Aug 28 21:45:00 CST 2012, time=2012-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=14709, encodeId=ce3014e0909, content=it's good !, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Mon Jan 26 15:16:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793152, encodeId=765d1e931524b, content=<a href='/topic/show?id=3bec151e616' target=_blank style='color:#2F92EE;'>#RBM5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15176, encryptionId=3bec151e616, topicName=RBM5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Aug 11 17:45:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038373, encodeId=a89d20383e38b, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Aug 13 14:45:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878049, encodeId=b2ca18e8049c3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Aug 28 21:45:00 CST 2012, time=2012-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=14709, encodeId=ce3014e0909, content=it's good !, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Mon Jan 26 15:16:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793152, encodeId=765d1e931524b, content=<a href='/topic/show?id=3bec151e616' target=_blank style='color:#2F92EE;'>#RBM5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15176, encryptionId=3bec151e616, topicName=RBM5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Aug 11 17:45:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038373, encodeId=a89d20383e38b, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Aug 13 14:45:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878049, encodeId=b2ca18e8049c3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Aug 28 21:45:00 CST 2012, time=2012-08-28, status=1, ipAttribution=)]
    2012-08-28 anminleiryan

相关资讯

Cell Reports:科学家破解癌细胞耐受药物MLN4924秘密

基于PDB文件1ndd利用PyMOL渲染构建NEDD8蛋白结构图,图片来自维基共享资源。 【Copyright ©版权Bioon.com所有,若未得到生物谷授权,请勿转载。】 对癌症患者而言,耐药性是一个严重性问题:药物治疗刚开始有一些疗效,但是过一段时间之后,不能发挥作用。如今,来自美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research In

J. Exp. Med.:阻断CDK蛋白可导致三阴性乳腺癌萎缩

根据PDB文件1nkp而构建出c-Myc(红色)与Max(蓝色)和DNA形成的复合物的结构。图片来自维基共享资源。 根据2012年3月9日发表在Journal of Experimental Medicine期刊上的一篇研究论文,抑制一种大量存在的促进生长的蛋白能够导致三阴性乳腺癌消退。 三阴性乳腺癌(triple-negative breast tumor)缺乏其他类型乳腺癌中存在的所有已知

Nat Biotechnol:治疗皮肤癌的黑色素瘤疫苗研究获新突破

梅奥诊所研究人员将人黑色素瘤细胞的DNA与一种狂犬病病毒进行基因组合后,提高老鼠的免疫系统功能进而根除皮肤癌。这种战略称为癌症的免疫疗法,即采用基因工程改造过的水泡性口炎病毒直接将黑色素瘤细胞来源的广谱基因传递带肿瘤内。在早期的研究中,60%的荷瘤小鼠在不到3个月的时间内就得到治愈,并且副作用也很少。 最新研究结果发表在本周的《自然生物技术》杂志上。 梅奥诊所分子医学系研究人员、文章合著者

JBC:肿瘤生物标记物hMSH2的识别机制

核蛋白hMSH2是DNA错配修复系统中的重要元件。之前的研究表明,hMSH2很可能是TCRγδ的一种蛋白配体。近日,来自中国医学科学院基础医学研究所的何维教授及其研究组发现:异位表达的人类肿瘤生物标记物hMSH2是一个新发现的内源性配体,可以被人类Vδ2 T细胞识别并引起先天的抗肿瘤抗病毒免疫反应。相关论文发表在3月20日的美国《生化周刊》(Journal of Biological Chemis

EMBO Mol Med:鉴定癌症类型的新技术

犹他州大学Huntsman癌症研究所的研究人员称他们已经发现了一种快速、准确且成本低廉的方法来确定引发癌症的遗传物质的重组即染色体易位情况。有关该方法的描述和研究结果发表在EMBO Molecular Medicine杂志上。 许多癌症类型是由肿瘤细胞中染色体易位导致的。虽然已发现数百种引发癌症的染色体易位,但目前检测方法有重大缺陷。 犹他州大学Huntsman癌症研究所主任Stephen

PLoS One:发现调节前列腺癌发展的miRNA以及治疗药物

去势抵抗性前列腺癌 (CRPC) 的发生促进了前列腺癌(PCa)病人的高死亡率,这在某种程度上归因于肿瘤干细胞(CSCs)的存在及出现。近期来自美国韦恩州立大学医学院的Fazlul H. Sarkar等人研究表明,解除对Let-7(一种miRNAs)表达的控制会促进PCa的发生和发展,并且这个过程能够被BR-DIM所改变。相关研究发表在3月19日美国《公共科学图书馆·综合(PLoS One)上。